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Understanding interactions between antibiotics used in combination is an important
theme in microbiology. Using the interactions between the antifolate drug trimethoprim
and the ribosome-targeting antibiotic erythromycin in Escherichia coli as a model, we
applied a transcriptomic approach for dissecting interactions between two antibiotics
with different modes of action. When trimethoprim and erythromycin were combined,
the transcriptional response of genes from the sulfate reduction pathway deviated from
the dominant effect of trimethoprim on the transcriptome. We successfully altered
the drug interaction from additivity to suppression by increasing the sulfate level in
the growth environment and identified sulfate reduction as an important metabolic
determinant that shapes the interaction between the two drugs. Our work highlights the
potential of using prioritization of gene expression patterns as a tool for identifying key
metabolic determinants that shape drug-drug interactions. We further demonstrated
that the sigma factor-binding protein gene crl shapes the interactions between the
two antibiotics, which provides a rare example of how naturally occurring variations
between strains of the same bacterial species can sometimes generate very different
drug interactions.
Keywords: transcriptomics, antibiotic interactions, sulfate reduction, trimethoprim (TMP), erythromycin (ERY),
E. coli
INTRODUCTION
A growing volume of microbiology research has been dedicated to characterizing drug-drug
interactions in combination antibiotic treatment, because understanding how and why antibiotics
interact with each other has the potential to help clinicians improve treatment efficacy, reduce
dosage-related side effects and slow the emergence of antibiotic resistance (Tamma et al., 2012;
Worthington and Melander, 2013; Mitosch and Bollenbach, 2014; Bollenbach, 2015; Wood,
2016). The use of high-throughput assays for measuring bacterial growth rate has accelerated the
identification and characterization of antibiotic interactions (Yeh et al., 2006; Wood et al., 2012;
Ocampo et al., 2014; Chevereau and Bollenbach, 2015; Zhou et al., 2015; Nguyen et al., 2016).
Pairwise interactions between antibiotics can be classified as additive, synergistic or antagonistic
(Figure 1A) based on whether their combined effects on bacterial growth inhibition are equal
to, greater than or less than those of their individual effects, respectively (Loewe, 1928, 1953;
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Bliss, 1939; Yeh et al., 2006; Foucquier and Guedj, 2015).
Suppression is a special type of antagonism in which the
combined growth inhibitory effect is weaker than that of one
antibiotic or both antibiotics alone (Yeh et al., 2006).
Our current understanding of the origins of antibiotic
interactions still lacks comprehensive mechanistic
underpinnings. There are several well-studied examples that
explain why drugs that target the same pathways tend to interact
synergistically. For example, trimethoprim and sulfamethoxazole
inhibit two steps in the tetrahydrofolic acid synthesis pathway.
Their synergistic interaction has been attributed to the drugs’
ability to potentiate each other’s inhibitory effects on key
metabolite synthesis within this pathway (Minato et al., 2018).
The synergism between two ribosome-targeting antibiotics of the
macrolide family, lankacidin and lankamycin, can be explained
by their ability to target neighboring sites in the ribosome
(Auerbach et al., 2010). For antibiotics that target unrelated
pathways, the ability of one drug to affect the uptake or efflux
of another has been proposed to be a mechanism that results
in drug interactions (Cokol et al., 2011; Brochado et al., 2018).
For example, the synergism between streptomycin and penicillin
was proposed to be due to the cell membrane-damaging effect of
penicillin, which in turn facilitates bacterial cell penetration by
streptomycin (Plotz and Davis, 1962). Conversely, antagonism
can emerge when one drug limits the proton motive force-
dependent uptake of another drug or increases its efflux through
efflux pumps, resulting in decreased intracellular concentration
of the latter (Brochado et al., 2018).
The suppressive effect of spiramycin, a ribosome-targeting
antibiotic, on trimethoprim has been attributed to non-optimal
regulation of ribosomal genes, which leads to an imbalance
between cellular DNA and protein contents in the presence of
trimethoprim-induced DNA stress (Bollenbach et al., 2009). This
mechanism also underlies the antagonism between ciprofloxacin
and tetracycline and has been proposed to hold more generally
for antibiotic pairs comprising a DNA synthesis inhibitor and
a protein synthesis inhibitor (Chait et al., 2007; Bollenbach
et al., 2009). More broadly, polysaccharide and ATP synthesis
in E. coli are key cellular processes that shape pairwise drug
interactions between six antibiotics with different modes of
action; supplementing growth medium with small molecule
adjuvants that target these cellular functions alters drug-drug
interactions in a predictable way (Chevereau and Bollenbach,
2015).
Erythromycin shares similarities with spiramycin with respect
to their inhibitory effect on translation elongation (Kirst
and Sides, 1989). Both are macrolide-type ribosome-targeting
bacteriostatic antibiotics that bind to the 50S large ribosomal
subunit, block nascent polypeptides (Hansen et al., 2002),
and trigger the cold shock response in E. coli (van Bogelen
and Neidhardt, 1990). Erythromycin is expected to suppress
trimethoprim. However, the interaction between erythromycin
and trimethoprim was experimentally characterized as additive
(Ocampo et al., 2014) or predicted to be additive against
E. coli (Wood et al., 2012). What causes this apparent
lack of a suppressive interaction between erythromycin and
trimethoprim? To address this question, we applied an RNA-Seq
transcriptomics approach to capture the effects of single
and combined antibiotic treatments on gene expression in
E. coli. Gene regulation responses often show conflicts when
antibiotics that generate different transcriptional responses are
combined. Bacteria often resolve such conflicts by prioritizing
gene expression to one of the two drugs or by averaging the
gene expression due to both drugs (Bollenbach and Kishony,
2011; Young and Elowitz, 2011). We explored whether this
phenomenon could help us identify genetic determinants that
shape the interactions between erythromycin and trimethoprim.
Notably, our study revealed that when the two antibiotics are
combined, the expression of sulfate reduction genes escaped the
stronger overall effect of trimethoprim on the transcriptome.
This unexpected transcriptomic response underlies the lack of a
suppressive interaction in a sulfate-limited growth environment.
In addition, we showed that the presence of an intact sigma
factor-binding protein gene crl also contributes to a suppressive
interaction between the two antibiotics. Overall, our findings
highlight the roles of gene expression prioritization patterns of
an essential metabolic pathway and a key genetic background
variation in shaping drug interactions.
MATERIALS AND METHODS
Growth Medium, Antibiotics and
Bacterial Strains
LB broth Miller (pH 7.4) was used as the default growth
medium throughout this study, and all chemicals were obtained
from Sigma-Aldrich (St. Louis, United States). Where required,
LB broth was supplemented with 2 mM sodium sulfate.
Trimethoprim (TMP) was dissolved in dimethyl sulfoxide, while
erythromycin (ERY) and spiramycin (SPR) were dissolved in
ethanol to obtain 50 mg/mL stock solutions. The E. coli MG1655
strain in this study is a crl-deficient strain used in a previous
work with a 777 bp IS1 transposable element insertion in the
crl coding region (Bollenbach et al., 2009). The E. coli BW25113
ancestral strain and the crl single gene knockout derivative
strain of BW25113 are from the Keio collection (Baba et al.,
2006). To account for the kanamycin resistance marker that is
present in the crl knockout strain, BW25113 was transformed
with the low copy number pUA66 plasmid (Zaslaver et al., 2006)
to generate the kanamycin-resistant BW25113/pUA66 control
strain. The IS1 insertion in crl of our MG1655 strain and the
intact crl in the BW25113 parental strain were verified using
the primer pair 5′-CAGGAAATCACCGACTGGAT-3′ and 5′-
CGACGTCGGTGCTACGTATT-3′ (Freddolino et al., 2012).
Growth Rate Measurement and Data
Analysis
Prior to each kinetic growth rate experiment in 96-well
microtiter plates, E. coli strains were pre-cultured overnight
for approximately 20 h in antibiotic-free LB broth with
shaking (225 rpm) at 37◦C. On the next day, antibiotic stock
solutions for trimethoprim and one of the two macrolides
(ERY or SPR) were diluted in LB broth to obtain linear
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FIGURE 1 | In contrast to another ribosome-targeting antibiotic spiramycin (SPR), erythromycin (ERY) does not suppress trimethoprim (TMP) when tested against a
crl-deficient MG1655 strain. (A) Schematic of different drug-drug interaction isoboles in a two-dimensional drug concentration space. Loewe additivity of drug-drug
interactions is used for quantifying effects of drug combinations. Lines of constant inhibition (isoboles) in the 2D drug concentration space represent combinations of
drugs A and B that result in same normalized growth rate. The four types of interactions shown are synergistic (green), additive (red), antagonistic (orange) and
suppressive (blue). (B) TMP and ERY show almost additive interaction against crl-deficient E. coli MG1655. Isoboles in grayscale represent exponential growth rates
normalized to that of the no-antibiotic treatment control in 2D concentration space. When tested against a crl-deficient E. coli MG1655 strain, ERY and TMP show
an additive interaction. In contrast, SPR exerted a mildly suppressive effect on TMP under the same experimental conditions.
concentration gradients, which were subsequently used to set
up two-dimensional antibiotic concentration gradients in clear,
flat-bottom 96-well microtiter plates with lids (Thermo Fisher
Scientific, United States). The overnight pre-culture was diluted
1:1,000 in 200 µl cultures with and without antibiotics. Six
technical replicates of cultures with no antibiotic treatment were
included in each microtiter plate as control. The microtiter plates
were incubated for 16–18 h at 37◦C with continuous shaking on a
Synergy H1 Hybrid Multi-Mode Reader (BioTek, United States).
Absorbance at the 600 nm wavelength (OD600) was measured
every 10 min. Only growth curves of sub-lethal antibiotic
treatments were retained for further analyses. Growth curves that
showed lethal effects associated with high concentrations of single
or combination antibiotic treatments were excluded even if an
initial period of transient growth can be recorded.
Calculation of exponential growth rates was performed
in MATLAB (MathWorks, United States). First, OD600
measurements from wells that contained blank LB broth
were subtracted from all data points. Blank-corrected absorbance
measurements (OD600) that lie within the early exponential
phase (defined here as 0.02 < OD600 < 0.18) were log-
transformed. An array of linear regression values within the
interval was calculated for each culture using all combinations of
six consecutive data points for every bacterial culture. A 60-min
sliding window determined the maximum exponential growth
rate within this interval. Normalized exponential growth rates
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of bacterial cultures with antibiotic treatments were calculated
by normalizing their maximum exponential growth rate to that
of the no-antibiotic treatment control in the same experiment.
Each growth rate experiment was performed three times to
obtain three independent biological replicates. Arrays of average
normalized exponential growth rates in the [0, 1] interval
were thus obtained for each experimental condition involving
different E. coli strains, antibiotic pairs or growth media, which
were noise-filtered using the ordfilter2 function with a round
filter. Isoboles representing the same levels of normalized
exponential growth rates in the two-dimensional concentration
space of antibiotic pairs (isocontours) were visualized using the
contour function.
RNA-Seq
Prior to RNA isolation, bacterial cultures were grown in the
same conditions as described above in LB medium (Miller).
Two biological replicates of total RNA samples were isolated for
each antibiotic-treatment and the no-treatment control (Table 1).
Eight technical replicates were included for every condition
for each biological replicate. After 3 h ± 20 min of growth,
exponential phase bacterial cultures (OD600 < 0.35) were mixed
with RNAprotect Bacteria Reagent (Qiagen, Germany), and
total RNA was extracted using the SV Total RNA Isolation
System (Promega, United States) according to the manufacturers’
instructions with minor modifications. The RNA integrity
numbers (RIN) of all the total RNA samples were assessed
using the Agilent RNA 6000 Nano Kit and Agilent 2100
Bioanalyzer (Agilent Technology, United States) and were in the
8.8 ≤ RIN ≤ 10 range.
Illumina high-throughput sequencing was performed by the
Vienna Biocenter Core Facility. Ribodepletion of total RNA was
carried out using the Ribo-Zero rRNA Removal Kit (Epicenter,
United States). mRNA library was generated using the NEBNext
Ultra Library Prep Kit for Illumina (NEB, United States). For
multiplexing, TruSeq adaptors were ligated to individual samples.
Paired-end sequencing was carried on HiSeq 2500 V4 with read
length of 125 bp (Illumina, United States).
TABLE 1 | Sample groups TMP, ERY, TMP + ERY and the no-antibiotic treatment




Control group without antibiotic treatment
TMP Trimethoprim-treatment resulting in 50% reduction in
exponential growth rate (IC50); concentration of
TMP = 0.0625 µg/mL
ERY Erythromycin-treatment resulting in 50% reduction in
exponential growth rate (IC50); concentration of
ERY = 42 µg/mL
TMP + ERY Combination treatment with trimethoprim and erythromycin,
both of which were used at their respective IC50
concentrations
TMP
(0.2 × IC50) + ERY
(0.6 × IC50)
Combination treatment with trimethoprim and erythromycin
that resulted in approximately 50% reduction in exponential
growth rate relative to the no-antibiotic control group
Transcriptomic Data Analysis
Raw Illumina reads were trimmed and filtered using the NGS
QC Toolkit (Patel and Jain, 2012). The 3′ and 5′ ends of raw
reads were trimmed when Phred score < 20. Trimmed reads that
were shorter than 125 bp were discarded. Next, filtered reads
with Phred score > 20 throughout 80% of their lengths were
retained, while reads with ambiguity in > 2% of all bases were
discarded. Illumina adaptors were removed using TrimGalore
(Martin, 2011). Using Bowtie 2, the trimmed and filtered reads
were mapped to the E. coli MG1655 reference genome with
gene annotations (genome assembly ASM584v2) from Ensembl
Bacteria (Langmead and Salzberg, 2012; Yates et al., 2016).
BAM/SAM file manipulations were carried out using SAMtools
commands for viewing, sorting and indexing (Li et al., 2009).
All BAM (∗.bam), BAM index (∗.bam.bai) and reference genome
files are available on the Dryad repository (see Supplementary
Table 1). Gene counts were extracted from the sorted and indexed
BAM files using the Python script HTSeq (Anders et al., 2014).
After excluding genes with no reads, the median sequencing
coverage was 683x.
Using the DESeq2 Bioconductor package (Anders and Huber,
2010; Anders et al., 2013), genes with an average of fewer than
10 reads per sample across all the experimental conditions were
discarded. For each gene, the geometric mean for gene counts
was calculated across all sample groups, which was applied as
the normalization factor for that gene. Within each sample, the
median of all normalized gene counts was applied as the size
factor for that sample in the second normalization step. For
principal component analysis (PCA), logarithmic transformation
of the normalized count data was carried out to remove the
dependence of the variance on the mean. PCA was performed
using default parameters of the plotPCA function. The PCA
score plot was generated using the 500 most variable genes across
all the sample groups in our dataset. Briefly, the covariance
matrix computed from the logarithm of normalized count
data was decomposed into eigenvectors, which were used as
weighting coefficients to calculate the principal component scores
(Todorov et al., 2018). Top/bottom gene loading on the PCA were
calculated using the Bioconductor package pcaExplorer (Marini
and Binder, 2019). Heat-map diagrams and dendrograms from
the two-way hierarchical clustering analysis of the 100 most
variable genes were generated using the heatmap.2 function.
For every gene, the logarithm of normalized gene counts was
transformed into Z-scores such that their mean is 0 and standard
deviation is 1 across all the sample groups.
For differential gene expression analysis, a negative binomial
general linear model was fitted for each gene, and the Wald test
was applied for significance testing. In samples that were treated
with one or two antibiotics, genes are classified as differentially
expressed relative to the no-treatment control group if their
adjusted P-values are less than 0.01 after controlling for false
discovery rate using Benjamini-Hochberg correction (Benjamini
and Hochberg, 1995). Differentially expressed genes were
compiled for five pairwise comparisons: (1) TMP against no-
drug control, (2) ERY against no-drug control, (3) TMP + ERY
against no-drug control, (4) TMP + ERY against ERY and (5)
TMP + ERY against TMP. Venn diagrams were constructed
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for the differentially expressed genes in pairwise comparisons
(1), (2) and (3). Pathway enrichment analysis was performed for
pairwise comparison (5) using the GAGE (Generally Applicable
Gene-set Enrichment) package (Luo et al., 2009). Enrichment
of the assimilatory sulfate reduction KEGG pathway (eco00920)
in a wider context of sulfur metabolism was visualized using
the Bioconductor package Pathview (Luo and Brouwer, 2013;
Kanehisa et al., 2016). Across pairwise comparisons (1), (2)
and (3), two-way hierarchical clustering analysis of average
log2 fold-change for cys genes was performed using the
heatmap.2 function.
Quantitative Real-Time PCR
In three biological replicates, E. coli MG1655 was incubated at
37◦C overnight with shaking in 2 mL antibiotic-free LB medium
as three independent cultures. On the next day, saturated pre-
cultures were diluted 1:500 in 2 mL fresh LB medium (Miller)
containing TMP, ERY + TMP or ERY + TMP + 2 mM
sodium sulfate, where ERY and TMP concentrations are 42
and 0.0625 µg/mL, respectively. After approximately 3 h of
further incubation with shaking (225 rpm), total RNA was
extracted from each bacterial pellet using a phenol-chloroformed
based method with QIAzol Lysis Reagent (Qiagen, Germany).
After treatment with DNase I solution at 37◦C (New England
Biolabs), 200 ng total RNA of each sample was added as
template for cDNA synthesis using the LunaScript RT SuperMix
Kit (New England Biolabs, United States) according to the
manufacturer’s instructions.
For qRT-PCR, equal volumes of each cDNA template
were amplified using Luna Universal qPCR Master Mix (New
England Biolabs, United States) and 0.25 µM gene-specific
oligonucleotide primer pairs for the target gene cysH (5′-
CTGAATGCCAAAGCTGGAAG-3′; 5′-AACGCCGAACTGGA
AAAACT-3′), as well as the internal reference genes rpoB (5′-
GTAAGGCACAGTTCGGTGGT-3′; 5′-ATTTCCTGCAGGG
TGTATGC-3′) and secA (5′-GGTAGTCGTAACGATCGCA-3′;
5′-TTTCCATCTCCGGTTCCAT-3′). The thermocycler profile
on the LightCycle 480 System (Roche, United States) comprised
60 s of initial denaturation at 95◦C, followed by 45 cycles
of denaturation (15 s at 95◦C), extension (30 s at 60◦C) and
fluorescence signal acquisition. Reactions were carried out in
two technical replicates for the three biological replicates. Using
the 2−11CT method, the relative expression levels of cysH
were normalized to the average expression of rpoB and secA.
Batch effect was accounted for by normalizing cysH expression
levels in the TMP + ERY and TMP + ERY + 2 mM sulfate
groups to those in the TMP-only reference group within each
set of biological replicates. Relative expression levels of cysH
are expressed in log2 fold-change. Error bars denote standard
error of the mean.
RESULTS
To characterize the interactions between trimethoprim (TMP)
and erythromycin (ERY) against an E. coli MG1655 wild-type
strain, we set up a two-dimensional concentration gradient of
the two antibiotics in LB medium and measured the optical
density (600 nm) of bacterial cultures over time using kinetic
assays. All experiments were carried out in LB medium at 37◦C
due to the availability of existing literature that focused on the
inhibitory effects of sub-lethal TMP or ERY treatments under
similar experimental conditions (Chevereau and Bollenbach,
2015; Giroux et al., 2017; Chen and Wang, 2021). The maximum
growth rates of bacteria were quantified during the early
exponential phase. The isoboles in the contour plots represent
pairwise combinations of antibiotic concentrations that resulted
in the same exponential growth rates relative to the no-
antibiotic treatment controls. The overall shape of the contours
suggests that the interaction between TMP and ERY is almost
additive (Figure 1B). We then performed the same experiment
for TMP and spiramycin (SPR) and found that SPR has a
clearly antagonistic, and even mildly suppressive effect on
TMP (Figure 1B), which is in agreement with previous results
despite the differences in experimental conditions (Bollenbach
et al., 2009). Our results confirmed that ERY and SPR show
different pairwise interactions with TMP under the growth
conditions in this study.
To identify genes and cellular pathways that shape the
interaction between TMP and ERY, we obtained the RNA-
Seq profiles of exponentially growing cultures treated with
single antibiotics at their half-maximal inhibitory concentrations
(IC50), as well as with a combination of these TMP and
ERY concentrations using paired-end Illumina HiSeq (Table 1).
Principal component analysis (PCA) was used to dissect how each
treatment contributes to the total variance in gene expression
and visualize the distribution of sample groups on a PCA score
plot (Figure 2A). TMP and ERY triggered distinct transcriptomic
responses and formed separate clusters. The position of the
TMP + ERY combination treatment group is highly similar
to that of TMP on PC1, which explains most of the variance
(78%). It is mostly on PC2, which captures 16% of the variance,
where the TMP + ERY group differs from the TMP group.
Differential gene expression analysis relative to the no-antibiotic
control group was performed (Supplementary File 1). The
Venn diagram in Supplementary Figure 1A shows that the
number of differentially expressed genes (Wald test: P < 0.01
after Benjamini-Hochberg correction) was much higher for TMP
(2,443 genes) compared to ERY (1,008 genes). Linear regression
analysis (Supplementary Figure 1B) revealed a high degree
of similarity between the log2 fold-changes of differentially
expressed genes that are common to the TMP and TMP + ERY
groups (coefficient of determination, R2 = 0.925). Overall,
the changes in transcriptomic profiles of the TMP + ERY
group are driven by the stronger transcriptomic responses
associated with TMP.
Next, we performed a two-way hierarchical clustering analysis
to contrast the gene expression profiles of the top 100 genes
with the greatest variations across all sample groups. Almost all
the genes in the TMP + ERY group displayed gene expression
responses that are consistent with those in the TMP group
(Figure 2B). The only clear exceptions are the cysH gene and cysIJ
operon from the assimilatory sulfate reduction pathway, which
belongs to the sulfur metabolism gene ontology (GO) category.
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FIGURE 2 | In TMP + ERY combination treatment, TMP exerts a much stronger overall effect on the transcriptomic response than ERY does. (A) TMP triggers a
different transcriptomic response than ERY but is similar to the combination treatment of TMP + ERY. Principal component 1 (PC1) explains 78% of the total variance
in gene expression, while PC2 accounts for 16%. TMP (blue) and ERY (yellow) trigger different transcriptomic responses, and the response to TMP + ERY treatment
(green) is more similar to TMP than it is to ERY. (B) Except for three sulfur metabolism related genes, TMP and TMP + ERY show a high degree of similarity in gene
expression profiles. Normalized gene counts from RNA-Seq were Z-score transformed across all sample groups before a two-way hierarchical clustering analysis
was performed based on the top 100 genes with the highest variance. The heatmap revealed that the transcriptomic responses for the TMP and TMP + ERY groups
were highly similar across four MultiFun gene ontology (GO) categories for 97 genes. The only exception is the sulfur metabolism category in which cysH and the
cysIJ operon do not display TMP-induced upregulation in the TMP + ERY group (inset).
The expression levels of these three genes in the TMP + ERY
group resemble those in the ERY and the no-drug control groups.
Differential gene expression analysis indicates that TMP led to
significant upregulation of cysH and cysIJ relative to the no-
antibiotic control group, while the TMP + ERY and ERY groups
showed expression levels that are similar to the control group
(Figure 2B inset). In other words, ERY in the TMP + ERY
combination treatment lowered the expression of cysH and cysIJ
relative to that in the TMP-treatment group.
We then examined the wider implications of the distinct
expression patterns for cysH and cysIJ. Sulfate reduction genes
are known to be differentially expressed when E. coli is treated
with TMP (Sangurdekar et al., 2011; Mitosch et al., 2017). The
assimilatory sulfate reduction pathway (Figure 3A) scavenges
extracellular sulfate and reduces intracellular sulfate to sulfide
via several intermediate steps (Sekowska et al., 2000). This
pathway is activated by the transcriptional activator CysB and
the N-acetyl-L-serine inducer (Ostrowski and Kredich, 1989;
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FIGURE 3 | Transcriptomic response of the assimilatory sulfate reduction pathway. (A) Genes and operons of the assimilatory sulfate reduction pathway. The
underlined genes and operons were included in the two-way hierarchical clustering analysis. cysG was excluded from this analysis due to its different regulatory
mechanism from all other genes in the sulfate reduction pathway. (B) The expression profiles of the sulfate reduction pathway follow the same trend as cysH and
cysIJ. Two-way hierarchical clustering analysis for genes of the sulfate reduction pathway and their transcriptional regulator gene cysB. With the exceptions of cysB
and sbp, all the cys genes in this pathway generally follow the same gene expression profiles as those of cysH and cysIJ across all the sample groups. (C) Average
log2 fold-change of sulfate reduction gene expression levels in the TMP, ERY and TMP + ERY groups relative to the no-drug control group.
Neidhardt, 1996). The end-product of the pathway, sulfide,
depletes the N-acetyl-L-serine inducer via the O-acetyl-L-serine
precursor, and thus exerts negative feedback on the expression of
cys genes (Neidhardt, 1996). CysB is also negatively regulated by
itself and N-acetyl-L-serine (Jagura-Burdzy and Hulanicka, 1981;
Neidhardt, 1996). We hypothesized that the distinct expression
patterns of cysH and cysIJ in the TMP + ERY group extends
to other sulfate reduction genes, because they share the same
transcriptional regulatory mechanism.
We performed a separate two-way hierarchical clustering
analysis for cysB and the sulfate reduction genes of Figure 3A
using row Z-scores and average log2 fold-change relative to the
no-drug control. With the exception of cysB and the periplasmic
sulfate-binding protein gene sbp, the expression profile of all the
cys genes in the sulfate reduction pathway followed the same
trend as cysH and cysIJ (Figures 3B,C). To exclude the possibility
that this was a consequence of differences in growth rates across
the four sample groups, we compared the TMP (IC50) and ERY
(IC50) groups with an additional TMP+ ERY sample group with
approximately 50% reduction in exponential growth rate. This
was achieved by reducing TMP and ERY concentrations for this
combination treatment group. Two-way hierarchical clustering
analysis confirmed that the TMP (0.2× IC50)+ ERY (0.6× IC50)
group clustered with ERY rather than with TMP (Supplementary
Figure 3), which is consistent with the trend in Figure 3B. This
suggests that the sulfate reduction genes are generally restrained
from responding to TMP when ERY is also present.
Treating E. coli with TMP in LB medium causes oxidative
stress (Giroux et al., 2017), which is expected to compromise
sulfate reduction and promote auto-oxidation of sulfide (Dolla
et al., 2006). LB medium is also considered to be a sulfate-poor
growth medium and contains approximately 0.1–0.15 mM of
sulfate (Kertesz, 2000). The upregulation of the sulfate reduction
pathway in the presence of TMP is a transcriptomic signature of
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sulfur limitation and decrease in intracellular sulfide availability
(Neidhardt, 1996; Gyaneshwar et al., 2005). Thus, it is consistent
with the negative feedback transcription regulation for this
pathway that counteracts sulfur limitation (Neidhardt, 1996).
Further links between oxidative stress and upregulation of the
sulfate reduction pathway had previously been established by
transcriptomic studies in which E. coli cultures grown in LB
medium were treated with oxidizing agents such as chlorine,
hydrogen peroxide, paraquat and sodium salicylate (Pomposiello
et al., 2001; Wang et al., 2009). These are consistent with
the TMP-induced upregulation of assimilatory sulfate reduction
genes we observed. However, it is conceivable that other TMP-
induced effects on one-carbon metabolism, as well as methionine
and S-Adenosyl methionine (SAM) synthesis could also have
contributed to the observed upregulation of the assimilatory
sulfate reduction pathway.
Using the TMP versus no-drug control and TMP + ERY
versus TMP pairwise comparisons, we performed gene set
analysis on the assimilatory sulfate reduction pathway and
neighboring nodes of the sulfur metabolism network (KEGG
annotation). ERY in the combination treatment suppressed the
upregulation of cys sulfate reduction genes when TMP+ ERY was
compared against TMP (Supplementary Figure 4B). A volcano
plot for the TMP+ ERY versus TMP comparison also confirmed
that cys genes were amongst some of the most downregulated
genes (Supplementary Figure 5). An intriguing observation that
emerged from the pathway analysis was the upregulation of
tauD and ssuE/ssuD, whose gene products allow taurine and
alkanesulfonates, respectively, to be utilized as alternative sulfur
sources under sulfate starvation (van der Ploeg et al., 1996;
Eichhorn et al., 1999). The lack of an expected upregulation
of the sulfate reduction pathway in the TMP + ERY group
implies a transcriptional response to sulfur limitation that results
in lower fitness.
To validate our key observation that ERY in the TMP + ERY
combination treatment suppresses the expression of the sulfate
reduction pathway, we performed quantitative real-time PCR
(qRT-PCR) on E. coli MG1655 that had been treated with TMP
and TMP + ERY. We focused on the PAPS reductase gene
cysH, which showed one of the highest variations in expression
levels across sample groups (Figure 3B). cysH expression was
normalized to the average expression of two stably expressed
essential genes (according to our RNA-Seq based differential
gene expression analysis), rpoB (encoding the RNA polymerase
β-subunit) and secA (encoding the protein translocase subunit
SecA) as internal reference genes. As expected, combining ERY
with TMP resulted in an approximately twofold reduction in
cysH expression level relative to the TMP-treated reference group
(Figure 4A). Under sulfur limitation, supplementing growth
media with sulfate is expected to stimulate the expression of
the sulfate reduction pathway (Pasternak et al., 1965; Wheldrake
and Pasternak, 1965). To verify this, we added 2 mM sodium
sulfate to the LB medium that contained TMP + ERY treated
MG1655 and observed an increase in average cysH relative
expression compared to that without exogenous sulfate. This
increase, however, did not fully offset the suppressing effect of
ERY on cysH expression.
We hypothesized that a transcriptional response to sulfur
limitation that is detrimental to fitness in the TMP + ERY
group shapes the drug interaction between TMP and ERY. To
test this hypothesis, we supplemented LB growth medium with
2 mM sodium sulfate and performed the same growth rate
assays as before in TMP + ERY two-dimensional concentration
space. Notably, ERY exerts a suppressive effect on TMP in the
presence of additional exogenous sulfate, especially at higher
TMP concentrations (Figure 4B). The disproportionately large
beneficial effect of sulfate on normalized growth rate in the
presence of both drugs altered the shape of the isoboles in the
2D drug concentration space (Supplementary Figure 6B).
To expand our characterization of TMP+ ERY interactions to
another key reference strain of E. coli, we performed additional
growth rate assays using the BW25113 strain (Grenier et al.,
2014). Although both BW25113 and MG1655 were derived from
the E. coli K12 ancestral strain, we observed that ERY exerted a
pronounced suppressive effect on TMP in the two-dimensional
contour plot for BW25113 (Figure 5A). A major difference
between BW25113 and the crl-deficient MG1655 strain used in
this study is that the former carries an intact crl gene. Crl is
a sigma factor-binding protein and transcription activator that
exerts global regulatory effects on the transcriptome by increasing
the affinity of RNA polymerase for the principal sigma factor
of the stationary phase σS (Typas et al., 2007; Cavaliere and
Norel, 2016; Cartagena et al., 2019; Xu et al., 2019). The 86
genes that are controlled by Crl in E. coli K-12 form 40% of
the RpoS regulon (Santos-Zavaleta et al., 2019). The loss of crl
can be detected in E. coli strains under laboratory settings that
favored the inactivation of the general stress response (Faure
et al., 2004), as well as in naturally-occurring pathogenic strains
of E. coli (Provence and Curtiss, 1992; Asadi et al., 2018). We
repeated the growth rate experiment using the BW25113 1crl
knockout mutant from the Keio collection to mimic the effects
of crl-inactivation in the MG1655 strain we used. As expected,
deleting crl abolished the suppressive drug interaction previously
observed (Figure 5B), yielding an antagonistic interaction.
Deleting crl substantially altered the susceptibility of BW25113
to TMP. The IC50 for TMP approximately doubled from
0.10 µg/mL to 0.21 µg/mL, while IC50 for ERY only decreased
marginally from 48 µg/mL to 42 µg/mL. On the vertical axes
of the contour plots, it is evident that the change in shapes of
isoboles was mainly driven by the increase in tolerance to TMP in
the absence of crl (Figure 5). The remaining difference between
TMP + ERY interactions in the MG1655 (additive; Figure 1B)
and BW25113 1crl strains (antagonistic; Figure 5B) is most likely
to be due to other variations in their genomes.
DISCUSSION
Applying a transcriptomic approach to identify genetic
determinants that affect the interaction between two antibiotics
with distinct modes of action is challenging, because the
transcriptomic signatures of individual antibiotic treatments
are superimposed. We used the interactions between TMP and
ERY as a model system, because ERY and SPR show different
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FIGURE 4 | Perturbing the sulfate reduction pathway by adding exogenous sulfate increases cysH expression level in TMP + ERY treated MG1655 and changes the
TMP + ERY interaction from additive to suppressive. (A) qRT-PCR validation of cysH expression. Relative to the TMP-treated MG1655 reference group, the
TMP + ERY treated group showed an approximately twofold reduction in cysH expression, which confirmed the role of ERY in suppressing cysH expression.
Supplementing the LB growth medium in which the TMP + ERY treated group is grown with 2 mM sulfate caused an increase in average cysH relative expression.
(B) ERY exerts suppression on TMP in growth medium supplemented with sulfate. Isoboles for TMP + ERY drug combinations when tested against the E. coli
MG1655 strain. Supplementing LB medium with sodium sulfate at 2 mM changed the interaction between TMP and ERY from additive to suppressive. Suppression
by ERY on TMP is stronger at higher concentrations of TMP in the presence of exogenous sulfate.
interactions with TMP (Figure 1B) despite their similarities
as ribosome-targeting antibiotics. TMP inhibits folic acid
metabolism, depletes key metabolites and induces DNA damage
(Sangurdekar et al., 2011; Giroux et al., 2017). Activating global
stress responses such as the SOS response and the ppGpp-
mediated stringent response has wide-ranging effects on the
transcriptome (Courcelle et al., 2001; Khil and Camerini-Otero,
2002; Durfee et al., 2008; Traxler et al., 2008). Despite this, the
transcriptomic response of the sulfate reduction pathway in the
TMP+ ERY group prioritized to that of ERY rather than to TMP
(Figure 3 and Supplementary Figure 3). By supplementing
the culture medium with exogenous sulfate and perturbing
the affected pathway (Figure 4A), we successfully changed the
additive interaction between TMP and ERY to a suppressive
interaction (Figure 4B). These results demonstrate that analyzing
prioritization patterns of conflicting transcriptomic responses
can be a useful tool for dissecting drug interaction mechanisms.
Given the disproportionately large beneficial effect of sulfate
addition on relative exponential growth rates when the two
drugs were combined, we argue that the suppressing effect of cys
upregulation by ERY is a transcriptional response that does not
maximize fitness. The sulfate reduction pathway is a subset of
sulfur metabolism, which is subject to strong negative feedback
control, because L-cysteine is one of the most toxic amino acids
at high concentrations (Datta, 1967; Avcilar-Kucukgoze et al.,
2016). In addition to the ability of sulfide to deplete O-acetyl-
L-serine (precursor to the N-acetyl-L-serine inducer), negative
feedback is also mediated by the inhibitory effect of L-cysteine on
the conversion of serine to O-acetyl-L-serine (Neidhardt, 1996).
TMP upregulated cys genes of the sulfate reduction pathway and
slightly downregulated cysB (Figures 3B,C), and these changes
are consistent with the transcriptional regulatory mechanism of
this pathway in response to sulfur limitation. The sulfate binding
protein gene sbp is the only sulfate reduction gene that showed
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FIGURE 5 | The suppressive effect of ERY on TMP requires the presence of the crl gene in BW25113. Isoboles for TMP + ERY drug combinations for the E. coli
BW25113/pUA66 and BW25113 1crl strains. Whereas ERY exerts a strong suppressive effect on TMP when tested against the BW25113/pUA66 strain which has
an intact crl gene (A), the suppression is removed when tested against the BW25113 1crl strain (B).
similar expression levels in both the TMP and TMP + ERY
groups (Figure 4B), but sbp is known to be activated more
specifically by sulfate starvation (van der Ploeg et al., 1996).
Given how tightly sulfur metabolism is regulated, it is surprising
that the cys genes displayed an unusual transcriptional response
in TMP + ERY (Figures 3B, 4A). As a ribosome-targeting
antibiotic, ERY is not expected to directly affect the intra- and
extracellular availability of metabolites for sulfur assimilation.
More metabolomic insights into the regulation of the cys genes in
response to combination treatment may reveal why TMP + ERY
treated cells displayed a transcriptional response that is unlikely
to be effective in counteracting the effects of TMP in terms of
oxidative stress and sulfate limitation.
We also demonstrated that the sigma factor-binding protein
gene crl plays a significant role in determining the interaction
between TMP and ERY against E. coli. This finding lends
support to the growing recognition that interactions between
the same combinations of antibiotics can sometimes differ
between bacterial species, as well as between different strains
of the same species (Brochado et al., 2018). For example, the
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interaction between nalidixic acid and tetracycline against several
multidrug resistant clones of Acinetobacter baumannii and E. coli
is synergistic, while their interactions in susceptible clones of
the same species are not (Gaurav et al., 2021). A previous study
showed that drug interactions between antibiotics representing
six main modes of action are surprisingly robust against most
single gene deletions in E. coli, and that only a very small
minority of single gene knockout strains produced qualitative
changes in drug interactions (Chevereau and Bollenbach, 2015).
Therefore, crl represents a rare example of single gene deletions
that caused such shifts in drug interactions. While it is not clear
if there are any interactions between the Crl-RpoS regulon and
the assimilatory sulfate reduction pathway, our findings hint
at the possibility that the effects of specific gene expression
patterns on drug interactions may be contingent on the presence
or absence of other genes such as transcriptional regulators.
Additional future efforts could also be directed toward systematic
discovery of specific genetic contexts in which alterations
in drug interactions arise due to variations between strains,
including the gain of antimicrobial resistance genes and loss of
transcriptional regulators.
In conclusion, drug interaction is a complex phenotype that
is determined by antibiotic modes of action (Cokol et al., 2011;
Ocampo et al., 2014; Chevereau and Bollenbach, 2015), gene
expression patterns (Bollenbach et al., 2009; Bollenbach and
Kishony, 2011), genetic variations across species and strains
(Chevereau and Bollenbach, 2015; Brochado et al., 2018; Gaurav
et al., 2021). Our study exemplifies that metabolite abundance
in the growth environment and gene prioritization patterns can
also affect drug-drug interactions. It is hoped that our work will
pave the way for future studies that employ a combination of
transcriptomic and complementary techniques to dissect drug-
drug interactions.
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